PREVICOX (firocoxib) Chewable Tablets

For dogs only.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

PREVICOX (firocoxib) Chewable Tablets were safely used during field studies. Adverse reactions observed. Dogs may have experienced more than one of the observed adverse reactions.

Adverse Reactions Seen in U.S. Field Studies

PREVICOX Chewable Tablets were safely used during field studies. Adverse reactions observed. Dogs may have experienced more than one of the observed adverse reactions. Owners should be advised to observe for signs of potential drug toxicity (see Adverse Reactions and Animal Safety) and be given a Client Information Sheet about PREVICOX Chewable Tablets.

PREVICOX Chewable Tablets are indicated for the control of pain and inflammation associated with osteoarthritis and for the control of post operative pain and inflammation associated with soft-tissue surgery in dogs.

PREVICOX (firocoxib) belongs to the coxib class of non-narcotic, non-steroidal anti-inflammatory drugs. Firocoxib is a selective COX-2 inhibitor. The empirical formula is C17H20O5S, and the molecular weight is 336.4. The structural formula is shown below:

In a separate dose tolerance safety study involving a total of six dogs (two control dogs and four treated dogs), firocoxib was administered orally to healthy juvenile (10-13 weeks of age) Bagle dogs at 5 mg/kg once daily for 14 days. At 10 mg/kg, one of the four treated dogs exhibited transient increases in ALP that remained within normal range. On histopathologic examination, a mild ulcer was found in one 14 mg/kg dog. This dog also had a decreased serum albumin level which returned to normal by the end of the study. One control and five of the six dogs exhibited transient decreases in红细胞压积, weight loss, nausea, weight gain, diarrhoea, increased activity, skin lesions, mild alopecia, and other changes. None of the observed adverse reactions were considered serious. No adverse effect was noted in a separate study comparing control groups of male and female dogs treated with a placebo or a COX-2 inhibitor. No adverse effect was noted in a separate study comparing control groups of male and female dogs treated with a placebo or a COX-2 inhibitor.

PREVICOX Chewable Tablets are available as round, beige to tan, half-scored tablets in two strengths, containing 57 mg or 227 mg firocoxib. Each tablet strength is supplied in 10 count and 30 count blister packages and 60 count bottles.

Information For Dog Owners: PREVICOX therapy and control (sham-dosed-pilled) in controlling postoperative pain and inflammation associated with soft-surgery. This study demonstrated that PREVICOX treated dogs had significantly lower need for rescue medication than the control (sham-dosed-pilled) group in controlling postoperative pain and inflammation associated with soft-surgery. This study demonstrated that PREVICOX treated dogs had significantly lower need for rescue medication than the control (sham-dosed-pilled) group in controlling postoperative pain and inflammation associated with soft-surgery.

Firocoxib is a COX-2 inhibitor (inhibition of COX-2 is responsible for the synthesis of inflammatory mediators). It is also a cyclooxygenase-reversible to be taken, stored, and disposed of properly. In a separate study comparing control groups of male and female dogs treated with a placebo or a COX-2 inhibitor, no adverse effect was noted. In a separate study comparing control groups of male and female dogs treated with a placebo or a COX-2 inhibitor, no adverse effect was noted. In a separate study comparing control groups of male and female dogs treated with a placebo or a COX-2 inhibitor, no adverse effect was noted.

Owners should be advised to observe for signs of potential drug toxicity (see Adverse Reactions and Animal Safety) and be given a Client Information Sheet about PREVICOX Chewable Tablets.

In a separate safety study, firocoxib was administered orally to healthy juvenile (10-13 weeks of age) Bagle dogs at 5 mg/kg once daily for 14 days. At 10 mg/kg, one of the four treated dogs exhibited transient increases in ALP that remained within normal range. On histopathologic examination, a mild ulcer was found in one 14 mg/kg dog. This dog also had a decreased serum albumin level which returned to normal by the end of the study. One control and five of the six dogs exhibited transient decreases in red blood cell mass, weight loss, nausea, weight gain, diarrhoea, increased activity, skin lesions, mild alopecia, and other changes. None of the observed adverse reactions were considered serious. No adverse effect was noted in a separate study comparing control groups of male and female dogs treated with a placebo or a COX-2 inhibitor. No adverse effect was noted in a separate study comparing control groups of male and female dogs treated with a placebo or a COX-2 inhibitor.

In a separate dose tolerance safety study involving a total of six dogs (two control dogs and four treated dogs), firocoxib was administered orally to healthy juvenile (10-13 weeks of age) Bagle dogs at 5 mg/kg once daily for 14 days. At 10 mg/kg, one of the four treated dogs exhibited transient increases in ALP that remained within normal range. On histopathologic examination, a mild ulcer was found in one 14 mg/kg dog. This dog also had a decreased serum albumin level which returned to normal by the end of the study. One control and five of the six dogs exhibited transient decreases in red blood cell mass, weight loss, nausea, weight gain, diarrhoea, increased activity, skin lesions, mild alopecia, and other changes. None of the observed adverse reactions were considered serious. No adverse effect was noted in a separate study comparing control groups of male and female dogs treated with a placebo or a COX-2 inhibitor. No adverse effect was noted in a separate study comparing control groups of male and female dogs treated with a placebo or a COX-2 inhibitor.

In a separate dose tolerance safety study involving a total of six dogs (two control dogs and four treated dogs), firocoxib was administered orally to healthy juvenile (10-13 weeks of age) Bagle dogs at 5 mg/kg once daily for 14 days. At 10 mg/kg, one of the four treated dogs exhibited transient increases in ALP that remained within normal range. On histopathologic examination, a mild ulcer was found in one 14 mg/kg dog. This dog also had a decreased serum albumin level which returned to normal by the end of the study. One control and five of the six dogs exhibited transient decreases in red blood cell mass, weight loss, nausea, weight gain, diarrhoea, increased activity, skin lesions, mild alopecia, and other changes. None of the observed adverse reactions were considered serious. No adverse effect was noted in a separate study comparing control groups of male and female dogs treated with a placebo or a COX-2 inhibitor. No adverse effect was noted in a separate study comparing control groups of male and female dogs treated with a placebo or a COX-2 inhibitor.